Gene Expression Profiling of Lymphoid Malignancies
- 1 February 2002
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 53 (1) , 303-318
- https://doi.org/10.1146/annurev.med.53.082901.103941
Abstract
▪ Abstract Comprehensive gene expression profiling using DNA microarrays is providing a molecular classification of cancer into disease categories that are homogeneous with respect to pathogenesis and clinical behavior. Gene expression profiling revealed that diffuse large B cell lymphoma (DLBCL) consists of at least two molecularly distinct diseases that are derived from distinct stages of B cell differentiation and have strikingly different clinical outcomes. By contrast, chronic lymphocytic leukemia (CLL) was found to be a single disease defined by a characteristic gene expression signature. Nonetheless, gene expression profiling distinguished two clinically divergent CLL subtypes and provided evidence that signaling through the B cell antigen receptor may play a role in the clinically aggressive subtype. Gene expression analysis also illuminated the mechanism of lymphomagenesis caused by BCL-6 translocations and provided evidence that the NF-κB signaling pathway is a new molecular therapeutic target in DLBCL.Keywords
This publication has 57 references indexed in Scilit:
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaThe Journal of Experimental Medicine, 2001
- Molecular definition of the germinal centre stage of B–cell differentiationPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2001
- Genomic Views of the Immune SystemAnnual Review of Immunology, 2000
- Genomic-scale gene expression profiling of normal and malignant immune cellsCurrent Opinion in Immunology, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21Published by Elsevier ,1994
- Germinal CentersAnnual Review of Immunology, 1994
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1989